USPTO serial 79361288
Reviewed by CopyMark Law Group
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary products for the treatment of liver diseases and disorders, endocrinological diseases and disorders, cardiovascular diseases and disorders, and cancer; diagnostic products for medical use, namely, medical diagnostic reagents and assays for testing of body fluids, medical diagnostic reagents, diagnostic preparations for medical use; pharmaceutical healthcare preparations for the treatment of liver diseases and disorders, endocrinological diseases and disorders, cardiovascular diseases and disorders, and cancer; medicinal preparations and substances for the treatment of liver diseases and disorders, endocrinological diseases and disorders, cardiovascular diseases and disorders, and cancer; biochemical preparations for medical or veterinary use for the treatment of liver diseases and disorders, endocrinological diseases and disorders, cardiovascular diseases and disorders, and cancer; biological and chemical reagents for medical or veterinary use; biological and chemical preparations for medical use for the treatment of liver diseases and disorders, endocrinological diseases and disorders, cardiovascular diseases and disorders, and cancer; biotechnological preparations for medical use, namely, for the treatment of liver diseases and disorders, endocrinological diseases and disorders, cardiovascular diseases and disorders, and cancer; biotechnological products for medical use, namely, medical preparations for the treatment of liver diseases and disorders, endocrinological diseases and disorders, cardiovascular diseases and disorders, and cancer; biological tissue cultures other than for medical or veterinary use; none of the foregoing relating to latex microspheres | ACTIVE | — |
| 042 | Technological services, namely, research and design for medical, biomedical and genetic purposes in the pharmaceutical field; technological services, namely, industrial analysis and research in the field of biotechnology; medical research and development in the pharmaceutical field; research and development in the field of biotechnology; research in the fields of biology; research in the field of biochemistry; development and evaluation of pharmaceutical products; testing of pharmaceutical products; research and development of new products; pharmaceutical research and development services; providing information and data relating to technological research and development in the field of biotechnology; providing research information and results in the field of biotechnology and medicine from an online searchable database; pharmaceutical drug development services; pharmaceutical research and development; development and research of new products for third parties in the fields of pharmaceuticals and biotechnology; research laboratory analysis services in the fields of biotechnology, pharmacotherapy, and pharmaceutical research and development; pharmaceutical and biological development and research services for third parties; evaluation of pharmaceutical product development; laboratory research in the field of medicinal and analytical chemistry, biology, pharmacology and toxicology; none of the foregoing relating to latex microspheres | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 13, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 13, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 13, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 18, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 18, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 18, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 17, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 17, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 17, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 29, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 29, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 29, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 29, 2025 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Sep 29, 2025 | PETG | PETITION TO REVIVE-GRANTED | — |
| Sep 29, 2025 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Jul 29, 2025 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 29, 2025 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 14, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 14, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 14, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 16, 2024 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 17, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Oct 29, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 15, 2024 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jan 15, 2024 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jan 15, 2024 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 7, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 6, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 6, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 26, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 6, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 6, 2023 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Jun 6, 2023 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Jun 6, 2023 | CREV | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED | — |
| Jun 6, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 5, 2023 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Apr 8, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 7, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 26, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 7, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 3, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 2, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |